Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 44,726 $ 23,054
Marketable securities 167,353 74,156
Receivable from collaboration   5,000
Accrued interest receivable 405 103
Prepaid expenses 2,131 1,208
Other current assets 2,100 23
Total current assets 216,715 103,544
Property and equipment, net 90 69
Other assets 1,363 634
Total assets 218,168 104,247
Current liabilities:    
Accounts payable 1,336 1,311
Accrued clinical trial expenses 7,877 2,929
Warrant liability 5,632 6,091
Other accrued liabilities 2,071 2,828
Facility loan   3,108
Accrued interest payable   43
Total current liabilities 16,916 16,310
Facility loan, less current portion   2,990
Deferred rent, net of current portion 2,039  
Total liabilities 18,955 19,300
Stockholders’ equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 100,000,000 shares authorized; 58,959,936 and 44,408,796 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 6 4
Additional paid-in capital 684,326 535,503
Accumulated other comprehensive loss (67) (44)
Accumulated deficit (485,052) (450,516)
Total stockholders’ equity 199,213 84,947
Total liabilities and stockholders’ equity $ 218,168 $ 104,247